Ardelyx, Inc. (NASDAQ:ARDX) Stock Has Average Price Target of $13.60

Shares of Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twelve analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $13.60.

ARDX has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Ardelyx in a research note on Friday, August 7th. Citigroup lowered their target price on Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Wedbush reaffirmed an “outperform” rating and set a $9.00 price target on shares of Ardelyx in a research report on Tuesday, August 18th. Zacks Research raised shares of Ardelyx from a “strong sell” rating to a “hold” rating in a report on Friday, October 16th. Finally, TD Cowen initiated coverage on shares of Ardelyx in a research report on Wednesday, November 4th. They set a “strong-buy” rating for the company.

View Our Latest Research Report on Ardelyx

Ardelyx Stock Performance

Shares of ARDX opened at $3.07 on Thursday. The company has a debt-to-equity ratio of 1.54, a quick ratio of 3.26 and a current ratio of 3.45. The stock has a 50 day moving average price of $3.26 and a two-hundred day moving average price of $5.09. The firm has a market capitalization of $771.72 million, a P/E ratio of -13.95 and a beta of 0.79. Ardelyx has a 52 week low of $2.80 and a 52 week high of $8.40.

Insider Transactions at Ardelyx

In other Ardelyx news, insider Eric Foster sold 8,562 shares of Ardelyx stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $33,049.32. Following the completion of the sale, the insider directly owned 409,410 shares in the company, valued at $1,580,322.60. The trade was a 2.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael Raab sold 58,574 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $3.86, for a total value of $226,095.64. Following the completion of the transaction, the chief executive officer owned 1,619,792 shares of the company’s stock, valued at $6,252,397.12. The trade was a 3.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 126,059 shares of company stock valued at $486,588. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Ardelyx

Several institutional investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Ardelyx during the second quarter valued at approximately $119,874,000. Jupiter Topco LLC bought a new position in shares of Ardelyx during the second quarter valued at approximately $27,043,000. AIGH Capital Management LLC purchased a new stake in Ardelyx in the second quarter worth $16,320,000. Bank of America Corp DE lifted its stake in Ardelyx by 5.8% in the first quarter. Bank of America Corp DE now owns 2,336,994 shares of the biopharmaceutical company’s stock worth $13,999,000 after acquiring an additional 128,301 shares during the period. Finally, Eversept Partners LP lifted its stake in Ardelyx by 30.0% in the first quarter. Eversept Partners LP now owns 2,229,446 shares of the biopharmaceutical company’s stock worth $13,354,000 after acquiring an additional 514,317 shares during the period. 58.92% of the stock is currently owned by hedge funds and other institutional investors.

About Ardelyx

(Get Free Report)

Ardelyx, Inc. is a biopharmaceutical company that develops and commercializes medicines for kidney and gastrointestinal diseases. Founded in 2007, the company has focused on treatments that work in the gastrointestinal tract, including therapies based on tenapanor. Ardelyx markets IBSRELA (tenapanor) in the United States for adults with irritable bowel syndrome with constipation. It also markets XPHOZAH (tenapanor) to help control serum phosphorus in adults with chronic kidney disease who are on dialysis.

Featured Articles

Analyst Recommendations for Ardelyx (NASDAQ:ARDX)

Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.